Lana Varney

An experienced trial lawyer in courts all over the country, Lana is known for developing cost-saving and effective legal strategies for defending multiple lawsuits filed in multiple venues. She creates unique approaches to assessing inventories of cases and assisting clients with defending against them. She currently serves as national counsel for several international companies defending claims against an osteoporosis medication, an afib drug, an anti-epilepsy drug, and female pelvic mesh medical devices. She has defended human blood products and plasma derived biologics, over the counter cough/cold products containing PPA, penile implants, seizure medications, bipolar treatments, and antidiuretic hormones.  Lana also assists clients with developing best practices and procedures to avoid litigation. She develops Litigation Avoidance Programs tailored to meet client specific company goals.

Formally a partner at Fullbright & Jawsorski for 26 years.

Experience

• Currently serving as national trial counsel for an international medical device company in female pelvic mesh litigation
• Serving as national trial counsel for a global pharmaceutical company in osteoporosis medication litigation involving allegations of osteonecrosis of the jaw and atypical femur fractures
• Serving as national counsel for a global pharmaceutical drug company in afib medication involving allegations of liver damage
• Serving as national counsel for a global pharmaceutical drug company in anti-epilepsy medication involving allegations of SJS/TENs
• Successfully defended an international pharmaceutical company in over the counter cough/cold medicine litigation in several trials while serving as national counsel (allegations involved strokes)
• Served as key strategist to national trial counsel for an international pharmaceutical company in Hemophilia/AIDS litigation and successfully defended the company in several trials
• Developed an effective Litigation Readiness Program for a Japanese pharmaceutical company, including teaching of best practices to President and Board of Directors and all key management executives
• Developed cost-effective inventory assessment protocol for use in mass torts for international drug and device companies